Aleph has achieved a major breakthrough in non-invasive neuroimaging, releasing the first high-resolution three-dimensional ultrasound scan of a living human brain captured through an intact skull. The milestone addresses a persistent bottleneck in brain-computer interface development and medical diagnostics: the inability to achieve MRI-level spatial resolution without invasive procedures or bulky equipment. Current neural recording technologies force a compromise between field of view and detail. Invasive electrode arrays capture minimal brain activity, while non-invasive methods like EEG and MEG suffer from fundamental physical limits that produce blurry data. Aleph’s approach leverages neurovascular coupling, mapping blood flow changes triggered by neuronal activity. By directing ultrasound waves through the skull and analyzing the scattering patterns of contrast agents, the system overcomes traditional diffraction limits. The breakthrough relies on ultrasound localization microscopy and intravenously administered microbubbles. These FDA-approved agents, composed of sulfur hexafluoride gas encased in lipid shells, reflect acoustic signals sharply. By injecting the bubbles sparsely and tracking their precise movement frame by frame, the technology reconstructs vascular networks at sub-wavelength precision. The resulting volumetric image reveals pial arteries, arterioles, and microvasculature with a resolution one hundred times greater than comparable computed tomography scans. In alignment with broader scientific collaboration, Aleph has open-sourced the complete processing pipeline and the associated imaging dataset. The company anticipates immediate clinical applications for conditions that leave subtle vascular imprints, including stroke, Alzheimer’s disease, and traumatic brain injury. These pathologies often manifest at microvascular scales that currently evade standard MRI and CT detection. The long-term objective is contrast-free neurovascular imaging. While microbubbles provide clear initial validation, future iterations aim to extract weaker signals directly from red blood cells. Aleph attributes this goal to two converging advancements: the miniaturization and cost reduction of ultrasound hardware, and the application of end-to-end machine learning to process terabytes of raw acoustic data. Current processing pipelines discard the majority of this information, but AI models trained on expansive datasets are expected to recover the faint signatures necessary for clinical adoption without contrast agents. This development marks a pivotal step toward general-purpose neural interfaces capable of mapping distributed cognitive processes with high fidelity. By simultaneously delivering comprehensive brain coverage and sub-millimeter resolution in a non-invasive format, Aleph’s ultrasound platform establishes a new foundation for next-generation brain monitoring and decoding technologies.